FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

View source ↗

Summary

FDA issued a safe-to-proceed letter allowing expanded access treatment for an investigational pancreatic cancer drug, daraxonrasib, by Revolution Medicines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Daraxonrasib

Snippet

FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.